SCHEMBL2811862

SCHEMBL2811862

O=C(O)CCCNC(=O)CCCCC(=O)NCCCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.60
EPHX2 P34913 3/20 0.58
KDM4E B2RXH2 1/20 0.57
ADRA1A P35348 1/20 0.56
LMNA P02545 3/20 0.55
ATM Q13315 1/20 0.55
TSHR P16473 2/20 0.55
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 1/20 0.54
SLC6A5 Q9Y345 1/20 0.54
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
PLA2G4A P47712 1/20 0.50
MAPK1 P28482 1/20 0.48
FAAH O00519 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31317640 0.98 PRMT1 (0.64) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL16620647 0.98 PRMT1 (0.64) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL31317673 0.98 PRMT1 (0.64) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL31317706 0.98 PRMT1 (0.64) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL30410272 0.95 ATM (0.55) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL31317660 0.95 PRMT1 (0.67) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL9717385 0.95 TSHR (0.59) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL24483715 0.93 PRMT1 (0.71) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL11468363 0.93 PRMT1 (0.71) PRMT1EPHX2KDM4EADRA1ALMNA
SCHEMBL8766995 0.93 PRMT1 (0.71) PRMT1EPHX2KDM4EADRA1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
WO-2025011640-A1 MEMANTINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 广州市恒诺康医药科技有限公司 2025-01-16 WO disclosed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 EP disclosed
CN-116322616-A Hair lightening compositions providing damage protection and sensory benefits and methods of use 欧莱雅 2023-06-23 CN disclosed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
WO-2022047081-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE HENRY DEREK (US) 2022-03-03 WO disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
US-5086104-A Mixture of thermoplastic resin, elastomer and amide compound, excellent toughtness, heat resistance and durability POLYPLASTICS CO., LTD. (JP) 1992-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 PRMT1 4663/4885EPHX2 301/4885KDM4E 2504/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB PRMT1 2654/4885EPHX2 3893/4885KDM4E 1615/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA PRMT1 2072/4885EPHX2 771/4885KDM4E 1109/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA PRMT1 1066/4885EPHX2 2034/4885KDM4E 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.